PVLA

Business Context and Reporting Period

Company: Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Palvella is a clinical-stage biopharmaceutical company focused on developing novel therapies for serious, rare skin diseases and vascular malformations. The company operates a single reportable segment. On December 13, 2024, the company completed a reverse merger with Legacy Palvella, changing its name and ticker symbol to PVLA. The company has no approved products and has never generated revenue from product sales.

Key Financial Metrics

Note: The company incurred significant non-cash interest expense related to a royalty agreement liability ($5.8 million in 2025 vs $3.9 million in 2024).

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased by $24.5 million (174%) year-over-year. This was driven primarily by increased clinical development costs for the lead product candidate, QTORIN rapamycin, including the Phase 3 SELVA and Phase 2 TOIVA trials, as well as increased headcount and public company costs.
• Net Loss: Net loss more than doubled to $41.7 million in 2025 compared to $17.4 million in 2024, reflecting the surge in operating expenses and non-cash interest accretion.
• Capital Structure: In December 2024, the company completed a reverse merger and PIPE financing. In February 2026 (subsequent to the reporting period), the company completed a public offering raising approximately $215.8 million in net proceeds.
• Liabilities: The royalty agreement liability increased to $17.8 million (from $11.9 million) due to accretion of interest expense based on updated probability assessments of commercialization.

Guidance, Outlook, and Management Commentary

Clinical Progress and Milestones

• QTORIN Rapamycin (Microcystic LMs): In February 2026, the company announced positive topline results from the Phase 3 SELVA study, meeting the primary endpoint (mLM-IGA) with a +2.13 improvement (p<0.001). The company plans to submit a pre-NDA meeting request in Q2 2026 and a rolling NDA submission in H2 2026.
• QTORIN Rapamycin (Cutaneous VMs): In December 2025, positive Phase 2 TOIVA study results were announced. A Phase 3 pivotal study is planned to commence in H2 2026.
• QTORIN Pitavastatin (DSAP): Announced in November 2025 as a new product candidate. A Phase 2 study is anticipated to initiate in H2 2026.

Liquidity and Capital Resources

As of December 31, 2025, the company held $58.0 million in cash. Management believes this, combined with the $215.8 million raised in the February 2026 public offering, is sufficient to fund operations for at least the next 12 months from the filing date. The company expects to continue incurring significant operating losses as it advances clinical trials and builds commercial infrastructure.

Risks and Contingencies

• Regulatory Risk: Success depends on FDA approval of QTORIN rapamycin. The FDA has commented that a placebo-controlled trial or additional endpoints may be required for microcystic LMs, though the company is proceeding with a baseline-controlled design.
• Financial Obligations: The company has a Development Funding and Royalties Agreement with Ligand Pharmaceuticals, requiring up to $5.0 million in remaining milestone payments and tiered royalties (8.0% to 9.8%) on future net sales.
• Manufacturing: The company relies entirely on third-party Contract Manufacturing Organizations (CMOs) and sole-source suppliers for certain components (e.g., pumps).

Key Facts for Investor Verification

• Revenue Status: Verify that the company has generated zero revenue from product sales to date and relies entirely on financing and grants.
• Cash Runway: Confirm the impact of the February 2026 public offering ($215.8M net proceeds) on the company's ability to fund operations through 2027 and beyond.
• Regulatory Pathway: Monitor the outcome of the pre-NDA meeting with the FDA in Q2 2026 regarding the acceptability of the Phase 3 SELVA study design for microcystic LMs.
• Ligand Agreement Liability: Review the volatility of the royalty agreement liability and derivative liabilities, which are based on subjective probability estimates of future sales and approval.
• Intellectual Property: Verify the expiration dates of key patents (ranging from 2038 to 2046) and the scope of protection for the QTORIN platform versus the active ingredients (rapamycin/pitavastatin) which are not patentable.